


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently Amended) A method of treating or preventing a disorder controlled by inhibition of the cholesterol ester transfer protein (CETP), comprising administering to a patient a therapeutically effective amount of a compound ~~Use of compounds~~ of the general formula (I)



in which

R¹ represents hydrogen, halogen, cyano, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, mono- or di-(C₁-C₄)-alkylamino, trifluoromethyl, trifluoromethoxy, hydroxy, vinyl or ethynyl,

R² represents a group of the formula



where

R¹¹ represents (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl, each of which may be mono- or polysubstituted by substituents selected from the group consisting of (C₃-C₆)-cycloalkyl, phenyl, (C₁-C₄)-alkoxy and fluorine, or represents (C₆-C₁₀)-aryl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, trifluoromethyl and trifluoromethoxy,

R¹² represents hydrogen or formyl,

R¹³ and R¹⁴ each represent (C₁-C₆)-alkyl,

R³ and R⁴ independently of one another represent hydrogen, halogen, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, (C₂-C₄)-alkenyl or (C₃-C₆)-cycloalkyl,

R⁵, R⁶ and R⁷ independently of one another represent hydrogen, halogen, cyano, nitro, hydroxy, trifluoromethoxy, formyl, (C₁-C₄)-alkoxy, (C₂-C₄)-alkenyl, (C₃-C₆)-cycloalkyl or represent (C₁-C₄)-alkyl which may be substituted by hydroxy, trifluoromethoxy, (C₁-C₄)-alkoxy or up to three times by fluorine,

R⁸ represents (C₁-C₈)-alkyl, (C₂-C₈)-alkenyl or (C₂-C₈)-alkynyl, each of which may be substituted by (C₃-C₈)-cycloalkyl, (C₁-C₄)-alkoxy, pyrrolyl, imidazolyl, triazolyl, tetrazolyl or phenyl which for its part is optionally substituted by (C₁-C₄)-alkyl,

represents (C₆-C₁₀)-aryl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano and nitro,

represents (C₁-C₈)-alkoxy or (C₂-C₈)-alkenyloxy, each of which may be substituted by (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkenyl or phenyl, (which for its part is optionally substituted by halogen, nitro or cyano) or up to five times by fluorine and/or chlorine,

represents (C₃-C₈)-cycloalkoxy or represents (C₆-C₁₀)-aryloxy which may be substituted by halogen, nitro or cyano,

represents mono- or di-(C₁-C₈)-alkylamino, (C₁-C₈)-alkylsulphonylamino or *N*-[(C₁-C₈)-alkyl]-(C₁-C₈)-alkylsulphonylamino,

or

represents a group of the formula -O-SO₂-R¹⁵, -O-C(O)-R¹⁶, -O-C(O)-NR¹⁷R¹⁸, -C(O)-OR¹⁹, -NR²⁰-C(O)-R²¹ or -NR²²-C(O)-NR²³R²⁴, where

R¹⁵ represents (C₁-C₈)-alkyl which may be substituted up to five times by fluorine, represents (C₃-C₈)-cycloalkyl or represents phenyl which may be substituted by halogen or (C₁-C₄)-alkyl,

R¹⁶ represents (C₁-C₁₀)-alkyl which may be substituted by phenyl or phenoxy (which for their part may each be mono- or disubstituted by halogen), by (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkenyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylthio, (C₂-C₆)-alkenylthio or up to six times by fluorine,

represents (C₃-C₁₂)-cycloalkyl which may be mono- or polysubstituted by substituents selected from the group consisting of phenyl, (C₂-C₆)-alkenyl, trifluoromethyl, (C₁-C₆)-alkyl, cyano and fluorine, where phenyl for its part

may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

represents (C₃-C₁₂)-cycloalkenyl which may be substituted up to three times by (C₁-C₄)-alkyl, trifluoromethyl or fluorine,

represents a 5- to 7-membered mono- or bicyclic saturated or partially unsaturated heterocycle which has up to two heteroatoms from the group consisting of N, O and S and which may be substituted up to two times by (C₁-C₄)-alkyl,

or

represents (C₆-C₁₀)-aryl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

R¹⁷ and R¹⁸ independently of one another represent hydrogen, (C₁-C₆)-alkyl which may be substituted by (C₁-C₄)-alkoxycarbonyl or up to three times by fluorine, represent (C₂-C₆)-alkenyl, (C₃-C₈)-cycloalkyl, (C₁-C₄)-alkylsulphonyl or represent phenyl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen and trifluoromethyl,

or

together with the nitrogen atom to which they are attached form a 4- to 12-membered mono-, bi- or tricyclic saturated or partially unsaturated heterocycle which may contain up to two further heteroatoms from the group

consisting of N, O and S and which may be substituted by phenyl or up to four times by (C₁-C₄)-alkyl,

R¹⁹ represents (C₁-C₆)-alkyl which may be substituted by (C₃-C₈)-cycloalkyl, represents (C₃-C₁₀)-cycloalkyl which may be substituted up to two times by (C₁-C₄)-alkyl or represents (C₂-C₆)-alkenyl,

R²⁰ represents hydrogen or (C₁-C₆)-alkyl,

R²¹ represents (C₁-C₈)-alkoxy, (C₁-C₈)-alkyl, (C₆-C₁₀)-aryl or represents (C₃-C₁₀)-cycloalkyl which may be substituted up to two times by (C₁-C₄)-alkyl,

R²² represents hydrogen or (C₁-C₆)-alkyl,

and

R²³ and R²⁴ independently of one another represent hydrogen, (C₁-C₆)-alkyl or (C₃-C₁₀)-cycloalkyl,

and

R⁹ and R¹⁰ independently of one another represent hydrogen or (C₁-C₄)-alkyl,

or a pharmaceutically acceptable salt thereof ~~and their pharmaceutically acceptable salts, solvates and solvates of the salts,~~

~~for the treatment and/or prevention of disorders controlled by inhibition of the cholesterol ester transfer protein (CETP) .~~

2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) The method of claim 1, wherein the disorder controlled by inhibition of the cholesterol ester transfer protein (CETP) is a ~~Use according to Claim 1 or 2 for the treatment and/or prevention of~~ cardiovascular disorder ~~disorders~~ .
5. (Currently Amended) The method of claim 1, wherein the disorder controlled by inhibition of the cholesterol ester transfer protein (CETP) is selected from ~~Use according to Claim 1 for the treatment and/or prevention of~~ hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias and ~~for~~ arteriosclerosis.
6. (Currently Amended) A compound ~~Compounds~~ of the formula (I) as defined in Claim 1 in which

R^8 represents a group of the formula $-O-C(O)-R^{16}$ where

R^{16} represents (C_1-C_{10}) -alkyl which may be substituted by phenyl or phenoxy (which for their part may each be mono- or disubstituted by halogen), by (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkenyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkylthio, (C_2-C_6) -alkenylthio or up to six times by fluorine,

represents (C_3-C_{12}) -cycloalkyl which may be mono- or polysubstituted by substituents selected from the group consisting of phenyl, (C_2-C_6) -alkenyl, trifluoromethyl, (C_1-C_6) -alkyl, cyano and fluorine, where phenyl for its part may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, (C_1-C_4) -alkyl and (C_1-C_4) -alkoxy,

represents (C₃-C₁₂)-cycloalkenyl which may be substituted up to three times by (C₁-C₄)-alkyl, trifluoromethyl or fluorine,

represents a 5- to 7-membered mono- or bicyclic saturated or partially unsaturated heterocycle which has up to two heteroatoms from the group consisting of N, O and S and which may be substituted up to two times by (C₁-C₄)-alkyl,

or

represents (C₆-C₁₀)-aryl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

and R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are each as defined in Claim 1.

7. (Currently Amended) A compound ~~Compounds~~ of the general formula (I) as defined in Claim 1 in which

R⁸ represents a group of the formula -O-C(O)-NR¹⁷R¹⁸ where

R¹⁷ and R¹⁸ independently of one another represent hydrogen, (C₁-C₆)-alkyl which may be substituted by (C₁-C₄)-alkoxycarbonyl or up to three times by fluorine, represent (C₂-C₆)-alkenyl, (C₃-C₈)-cycloalkyl, (C₁-C₄)-alkylsulphonyl or represent phenyl which may be mono- or disubstituted by identical or different substituents from the group consisting of halogen and trifluoromethyl

or

together with the nitrogen atom to which they are attached form a 4- to 12-membered mono-, bi- or tricyclic saturated or partially unsaturated heterocycle which may contain up to two further heteroatoms from the group consisting of N, O and S and which may be substituted by phenyl or up to four times by (C₁-C₄)-alkyl,

and R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are each as defined in Claim 1.

8. (Currently Amended) A compound ~~Compounds~~ of the formula (I) as defined in Claim 1 in which

R⁸ represents a group of the formula -C(O)-OR¹⁹ where

R¹⁹ represents (C₁-C₆)-alkyl which is substituted by (C₃-C₈)-cycloalkyl or represents (C₃-C₁₀)-cycloalkyl which may be substituted up to two times by (C₁-C₄)-alkyl,

and R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁹ and R¹⁰ are each as defined in Claim 1.

9. (Currently Amended) A compound ~~Compounds~~ of the formula (I) as defined in Claim 1 in which

R⁸ represents a group of the formula -NR²⁰-C(O)-R²¹ where

R²⁰ represents hydrogen or (C₁-C₆)-alkyl,

and

R^{21} represents (C₁-C₈)-alkoxy, (C₁-C₈)-alkyl, (C₆-C₁₀)-aryl or represents (C₃-C₁₀)-cycloalkyl which may be substituted up to two times by (C₁-C₄)-alkyl,

and $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^9$ and R^{10} are each as defined in Claim 1.

10. (Currently Amended) A compound ~~Compounds~~ of the formula (I) as defined in Claim 1 in which

R^8 represents a group of the formula $-NR^{22}-C(O)-NR^{23}R^{24}$ where


R^{22} represents hydrogen or (C₁-C₆)-alkyl,

and

R^{23} and R^{24} independently of one another represent hydrogen, (C₁-C₆)-alkyl or (C₃-C₁₀)-cycloalkyl,

and $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^9$ and R^{10} are each as defined in Claim 1.


11. (Currently Amended) A compound ~~Compounds~~ of the formula (I-A)



in which

R^5 , R^6 and R^7 independently of one another represent hydrogen, fluorine, chlorine, bromine, cyano or represent methyl or ethyl which may be substituted by methoxy or up to three times by fluorine,

R^8 represents a group of the formula



where

R^{17} and R^{18} independently of one another represent hydrogen, (C₁-C₆)-alkyl which may be substituted up to three times by fluorine, represent (C₃-C₆)-alkenyl or represent (C₃-C₆)-cycloalkyl,

or

together with the nitrogen atom to which they are attached form a 4- to 10-membered mono-, bi- or tricyclic saturated or partially unsaturated heterocycle which may contain an oxygen atom as further heteroatom and which may be substituted up to four times by methyl,

R^{25} and R^{26} together with the carbon atom to which they are attached represent (C₃-C₁₀)-cycloalkyl which may be substituted up to four times by substituents selected from the group consisting of fluorine, methyl and trifluoromethyl, represent (C₅-C₁₀)-cycloalkenyl which may be substituted up to two times by methyl or represent a 5- to 7-membered saturated or partially saturated mono- or bicyclic heterocycle having a ring oxygen atom,

and


R^{27} represents hydrogen, (C₁-C₄)-alkyl, cyano or trifluoromethyl,

R^{10} represents hydrogen, methyl or ethyl,

and

R^{11} represents (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl, each of which may be mono- to trisubstituted by substituents selected from the group consisting of cyclopropyl, cyclobutyl, methoxy and fluorine.


12. (Currently Amended) A compound ~~Compounds~~ of the formula (I-B)



in which

R^5 , R^6 and R^7 independently of one another represent hydrogen, fluorine, chlorine, bromine, cyano or represent methyl or ethyl which may be substituted by methoxy or up to three times by fluorine,

R^8 represents a group of the formula



where

R^{17} and R^{18} independently of one another represent $(\text{C}_1\text{-C}_6)$ -alkyl which may be substituted up to three times by fluorine, represent $(\text{C}_3\text{-C}_6)$ -alkenyl or represent $(\text{C}_3\text{-C}_6)$ -cycloalkyl,

or

together with the nitrogen atom to which they are attached form a 4- to 10-membered saturated mono- or bicyclic heterocycle which may contain an oxygen atom as further heteroatom and which may be substituted up to two times by methyl,

R^{25} and R^{26} together with the carbon atom to which they are attached represent $(\text{C}_3\text{-C}_{10})$ -cycloalkyl which may be substituted up to four times by substituents selected from the group consisting of fluorine, methyl and trifluoromethyl, represent $(\text{C}_5\text{-C}_7)$ -cycloalkenyl, 7-oxabicyclo[2.2.1]heptanyl or represent 7-oxabicyclo[2.2.1]hept-5-enyl,

and

R^{27} represents methyl, ethyl, propyl, cyano or trifluoromethyl,

R^{10} represents hydrogen, methyl or ethyl

and

R¹¹ represents (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl, each of which may be mono- to trisubstituted by substituents selected from the group consisting of cyclopropyl, cyclobutyl, methoxy and fluorine.

13. (Currently Amended) A method of treating or preventing a disorder controlled by inhibition of the cholesterol ester transfer protein (CETP), comprising administering to a patient a therapeutically effective amount of a compound of claim 11 or 12 ~~Use of compounds of the formulae (I), (I-A) and (I-B) as defined in Claims 6 to 12 for preparing medicaments for the treatment and/or prevention of disorders controlled by inhibition of the cholesterol ester transfer protein (CETP) .~~
14. (Cancelled)
15. (Cancelled)
16. (Currently amended) The method of claim 13, wherein the disorder controlled by inhibition of the cholesterol ester transfer protein (CETP) is a cardiovascular disorder ~~Use according to Claim 13 or 14 for the treatment and/or prevention of cardiovascular disorders .~~
17. (Currently amended) The method of claim 16, wherein the cardiovascular disorder is selected from ~~Use according to Claim 16 for the treatment and/or prevention of~~ hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias and ~~for~~ arteriosclerosis.
18. (Currently amended) A method of treating or preventing a disorder controlled by inhibition of the cholesterol ester transfer protein (CETP), comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition ~~Medicaments ,~~

comprising a compound of the formula (I), as defined in claim 1, a compound of claim 11 or a compound of claim 12 ~~(I-A) or (I-B) as defined in Claims 1 to 12,~~ for the treatment and/or prevention of disorders controlled by inhibition of the cholesterol ester transfer protein (CETP) .